Friedemann Honecker

11PUBLICATIONS
23CO-AUTHORS
Haematological tumoursCheminformatics and quantitative structure-activity relationshipsMolecular targetsSpeciation and extinctionCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 17, 2026
Class 3 MAP2K1 mutations are associated with frequent relapse and multiple treatment lines in multi-system Langerhans cell histiocytosis.

|Jan 22, 2024
Anticancer Activity of the Marine Triterpene Glycoside Cucumarioside A<sub>2</sub>-2 in Human Prostate Cancer Cells.

Ekaterina S Menchinskaya, Sergey A Dyshlovoy, Simone Venz

|Apr 20, 2022
Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.

Dennis M Timmerman, Thomas F Eleveld, Sruthi Sriram

|Dec 18, 2020
Marine Compounds and Cancer: Updates 2020.

Sergey A Dyshlovoy, Friedemann Honecker

|Jan 18, 2020
Marine Drugs Acting as Autophagy Modulators.

Sergey A Dyshlovoy, Friedemann Honecker

|Jan 01, 2020
Marine Compounds and Cancer: The First Two Decades of XXI Century.

Sergey A Dyshlovoy, Friedemann Honecker

Pageof 2

Frequent Collaborators

7 joint publications

Sergey Dyshlovoy

2 joint publications

Christoph Oing

1 joint publications

Wael Y Mansour

1 joint publications

Felix Bremmer